{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:36Z","timestamp":1787161296600,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["15411962000"],"award-info":[{"award-number":["15411962000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13048-016-0300-5","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T23:17:04Z","timestamp":1485299824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)"],"prefix":"10.1186","volume":"10","author":[{"given":"Zheng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhu","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"issue":"2","key":"300_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"300_CR2","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0020-7292(12)60025-3","volume":"119","author":"JS Berek","year":"2012","unstructured":"Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2:S118\u201329.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"300_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih I-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am J Surg Pathol. 2010;34(3):433\u201343.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"300_CR4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","volume":"20","author":"HJ Mackay","year":"2010","unstructured":"Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945\u201352.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"300_CR5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","volume":"114","author":"DM Gershenson","year":"2009","unstructured":"Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114(1):48\u201352.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"300_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140(3):457\u201362.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"300_CR7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2008.01.035","volume":"198","author":"SC Plaxe","year":"2008","unstructured":"Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198(4):459. e1-8; discussion e8-9.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 2","key":"300_CR8","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.ijgo.2015.06.010","volume":"131","author":"J Prat","year":"2015","unstructured":"Prat J. Pathology of cancers of the female genital tract. Int J Gynaecol Obstet. 2015;131 Suppl 2:S132\u201345.","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"300_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","volume":"10","author":"KM Schmeler","year":"2008","unstructured":"Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep. 2008;10(6):519\u201323.","journal-title":"Curr Oncol Rep"},{"issue":"9 Suppl 3","key":"300_CR10","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","volume":"24","author":"C Gourley","year":"2014","unstructured":"Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S9\u201313.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 1","key":"300_CR11","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","volume":"27","author":"DM Gershenson","year":"2016","unstructured":"Gershenson DM. Low-grade serous carcinoma of the ovary or peritoneum. Ann Oncol. 2016;27 Suppl 1:i45\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"300_CR12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","volume":"108","author":"KM Schmeler","year":"2008","unstructured":"Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108(3):510\u20134.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"300_CR13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","volume":"128","author":"J Escobar","year":"2013","unstructured":"Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, et al. Quantification of ER\/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128(2):371\u20136.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"300_CR14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","volume":"26","author":"KK Wong","year":"2007","unstructured":"Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007;26(4):404\u20139.","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"300_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","volume":"125","author":"DM Gershenson","year":"2012","unstructured":"Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012;125(3):661\u20136.","journal-title":"Gynecol Oncol"},{"key":"300_CR16","volume-title":"WHO Classification of tumors of female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Herrington CS, Young RH. WHO Classification of tumors of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.","edition":"4"},{"issue":"9","key":"300_CR17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh W, Koebel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853\u201362.","journal-title":"Lancet Oncol"},{"issue":"16","key":"300_CR18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2010.33.2023","volume":"29","author":"DL Rimm","year":"2011","unstructured":"Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011;29(16):2282\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"300_CR19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2008.12.018","volume":"113","author":"X-Y Yang","year":"2009","unstructured":"Yang X-Y, Xi M-R, Yang K-X, Yu H. Prognostic value of estrogen receptor and progesterone receptor status in Chinese young ovarian carcinoma patients. Gynecol Oncol. 2009;113(1):99\u2013104.","journal-title":"Gynecol Oncol"},{"key":"300_CR20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1757-2215-3-14","volume":"3","author":"B Nodin","year":"2010","unstructured":"Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.","journal-title":"J Ovarian Res"},{"issue":"12","key":"300_CR21","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1002\/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8","volume":"72","author":"K Friedrichs","year":"1993","unstructured":"Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641\u20137.","journal-title":"Cancer"},{"issue":"4","key":"300_CR22","first-page":"789","volume":"35","author":"S Buchholz","year":"2009","unstructured":"Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol. 2009;35(4):789\u201396.","journal-title":"Int J Oncol"},{"issue":"5","key":"300_CR23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000615","volume":"40","author":"E Okoye","year":"2016","unstructured":"Okoye E, Euscher ED, Malpica A. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution. Am J Surg Pathol. 2016;40(5):627\u201335.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"300_CR24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2014.12.018","volume":"136","author":"JD Seidman","year":"2015","unstructured":"Seidman JD, Vang R, Ronnett BM, Yemelyanova A, Cosin JA. Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification. Gynecol Oncol. 2015;136(2):336\u201340.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"300_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2014.12.003","volume":"41","author":"C Della Pepa","year":"2015","unstructured":"Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41(2):136\u201343.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"300_CR26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ygyno.2012.02.028","volume":"125","author":"CG Hannibal","year":"2012","unstructured":"Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecol Oncol. 2012;125(3):655\u201360.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"300_CR27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496\u2013504.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"300_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","volume":"108","author":"DM Gershenson","year":"2006","unstructured":"Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108(2):361\u20138.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"300_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2009.05.045","volume":"114","author":"H Arias-Pulido","year":"2009","unstructured":"Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 2009;114(3):480\u20135.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"300_CR30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12094-008-0213-x","volume":"10","author":"A Garcia-Velasco","year":"2008","unstructured":"Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colorner R, Cortes-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2\/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10(6):367\u201371.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"300_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic Role of Hormone Receptors in Ovarian Cancer A Systematic Review and Meta-Analysis. Int J Gynecol Cancer. 2013;23(1):25\u201333.","journal-title":"Int J Gynecol Cancer"},{"key":"300_CR32","doi-asserted-by":"crossref","unstructured":"van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015.","DOI":"10.1016\/j.ygyno.2015.06.032"},{"issue":"3","key":"300_CR33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1048-891x.2004.014304.x","volume":"14","author":"CH Chien","year":"2004","unstructured":"Chien CH, Chen CH, Lee CYG, Chang TC, Chen RJ, Chow SN. Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. Int J Gynecol Cancer. 2004;14(3):451\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"300_CR34","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0959-8049(97)00166-4","volume":"33","author":"M Mandai","year":"1997","unstructured":"Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, et al. Messenger ribonucleic acid expression of LH\/hCG receptor gene in human ovarian carcinomas. Eur J Cancer. 1997;33(9):1501\u20137.","journal-title":"Eur J Cancer"},{"key":"300_CR35","doi-asserted-by":"crossref","first-page":"25408","DOI":"10.1038\/srep25408","volume":"6","author":"Z Feng","year":"2016","unstructured":"Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep. 2016;6:25408.","journal-title":"Sci Rep"},{"issue":"2","key":"300_CR36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijpharm.2013.06.038","volume":"453","author":"X Zhang","year":"2013","unstructured":"Zhang X, Chen J, Kang Y, Hong S, Zheng Y, Sun H, et al. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone beta 81-95 peptide show effective antitumor activity against ovarian carcinoma. Int J Pharm. 2013;453(2):498\u2013505.","journal-title":"Int J Pharm"},{"issue":"2","key":"300_CR37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00404-012-2335-1","volume":"286","author":"JB Engel","year":"2012","unstructured":"Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet. 2012;286(2):437\u201342.","journal-title":"Arch Gynecol Obstet"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-016-0300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:59:42Z","timestamp":1498366782000},"score":1,"resource":{"primary":{"URL":"http:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-016-0300-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1186\/s13048-016-0300-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]},"article-number":"7"}}